Shots:

• Xencor to receive an upfront- development- regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for cancer
• Xencor to utilize its XmAb technology for the development of bispecific Ab candidates against Astellas’ targets & will take care of initial characterization of molecules. Astellas will be responsible for all preclinical- clinical- development- regulatory and commercial activities
• Xencor’s XmAb technology consists of Fc domains enabling Abs to bind two or more targets with changes in the structure of mAb resulting novel therapies for cancer  

Ref: Xencor | Image: Astellas